Vanqua Bio

Vanqua Bio will join the complement industry leaders at the 8th Annual Complement-Based Drug Development Summit in Boston from December 10 –12.     CSO Kevin Hunt will present on Vanqua’s development candidate VQ-201 and first-in-class CNS-penetrant C5aR1 antagonists.     The presentation, “Discovery of Next Generation C5aR1 Antagonists for Peripheral and CNS Indications: Enhancing Target Coverage While Reducing Safety Liabilities,” will take place on Thursday, December 12, at 12:00 PM ET.     Read the full press release: https://lnkd.in/etRknk-h   #Alzheimers #NeurodegenerativeDisease 

The Vanqua Bio team recently celebrated our five-year anniversary! We are proud of the progress we’ve made over the last five years and excited about the opportunities ahead. Most recently, our development candidate, VQ-101, a novel GCase activator for the treatment of GBA-Parkinson’s Disease, demonstrated positive interim results in healthy volunteers, and initiated dosing of GBA-PD patients in Phase 1b. Many thanks to our team, advisors, investors, and the PD community, whose passion and commitment empower our work. We look forward to many more years of innovation, achievement, and growth

We’re #hiring a new Scientist Neuroinflammation in Chicago, Illinois. Apply today or share this post with your network.

Please join us in welcoming Lyly Truong to the Clinical Operations team at Vanqua Bio. Lyly is joining us as a Sr. Clinical Trial Manager where she will begin working on Vanqua Bio’s lead clinical program. Lyly’s expertise in Clinical Trial Management will be critical in achieving our goals for 2024 and beyond. We are excited to have Lyly on the team and we can’t wait to see what she accomplishes in her career at Vanqua Bio. #Welcometotheteam #VanquaBio

We were pleased to join the academia and industry professionals at the 16th annual Parkinson’s Disease Therapeutics Conference hosted by The Michael J. Fox Foundation for Parkinson's Research. It was a wonderful opportunity to connect with fellow leaders committed to developing innovative and critically needed therapies for #ParkinsonsDisease. Jack Beyer, Kevin Hunt, Omer Siddiqui, Jonathan Silverstein, Daniel Ysselstein, Adam Knight, PhD

A warm welcome to Maurizio Facheris, M.D. who joined Vanqua Bio as Chief Medical Officer. Dr. Facheris’ first-hand experience of taking #ParkinsonsDisease therapies from early phase development to approval will be instrumental as the company advances VQ-101 into late-stage development.    Dr. Facheris’ previous experience includes the roles of Senior Medical Director in Neuroscience Development at AbbVie and Senior Associate Director of Research Programs at the Michael J. Fox Foundation for Parkinson’s Research. https://lnkd.in/eqRzbQct

We are pleased to share positive interim results from our Phase 1 clinical study of VQ-101, a small molecule allosteric activator of GCase. In healthy volunteers in Phase 1a, VQ-101 demonstrated good tolerability, robust lysosomal GCase activation, and pharmacokinetics consistent with once daily dosing. The study, conducted at Centre for Human Drug Research, has advanced to the Phase 1b portion in patients with Parkinson’s disease. https://lnkd.in/eqRzbQct

Vanqua Bio will participate in two upcoming scientific conferences: Grand Challenges in Parkinson’s Disease Symposium and International Parkinson and Movement Disorder Society's #MDSCongress. For details, read the full press release: https://lnkd.in/eSQp-FQR   #ParkinsonsDisease

Please join us in welcoming Tim Daly to the Finance team at Vanqua Bio. Tim is joining us as Vice President of Finance and Corporate Controller and will play a key role in managing our operational and finance infrastructure. We are excited to have Tim on the team and we can’t wait to see what he accomplishes in his career at Vanqua Bio. #Welcometotheteam #VanquaBio

Today, on #WorldBrainDay, Vanqua Bio joins the neurological community to raise critical awareness of brain health. Neurological disorders can affect anyone, regardless of age, ethnicity, gender or socioeconomic status. Everyone has a human right to brain health. Our team remains committed to discovering and developing innovative therapies capable of effectively slowing or halting the progression of neurodegenerative disorders, including #ParkinsonsDisease. To learn more about #WBD2024, go to https://lnkd.in/dQiTq4FU